CORCEPT THERAPEUTICS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.76 USD | +0.85% |
|
+12.83% | -14.96% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Corcept Therapeut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Companyâs portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
27.53
USD
Average target price
43.6
USD
Spread / Average Target
+58.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.96% | 2.87B | |
| +31.02% | 682B | |
| +30.35% | 586B | |
| -3.62% | 364B | |
| +18.10% | 327B | |
| +3.94% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.20% | 165B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Transcript : Corcept Therapeutics Incorporated, Q2 2023 Earnings Call, Aug 02, 2023
